Archives 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 December 19, 2019 Admission to trading on Euronext Growth Brussels Read More December 17, 2019 Publication of Information Note – In advance to admission to trading on Euronext Growth Brussels Read More December 13, 2019 Dual listing on Euronext growth Brussels Read More December 11, 2019 Share price volatility Read More December 03, 2019 ImmuPharma to present at Biotech Showcase™ 2020 in San Francisco Read More December 02, 2019 TR1 – Notification of major interest in shareholdings Read More November 28, 2019 ImmuPharma and Avion Pharmaceuticals sign exclusive licence Read More September 30, 2019 INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2019 Read More July 04, 2019 TR1 – Notification of Major Interest – Lanstead Capital Investors Read More July 02, 2019 TR1 – Notification of Major Shareholding Read More June 28, 2019 2019 Annual General Meeting – All resolutions passed Read More June 28, 2019 Primary endpoint successfully met from the open label extension study evaluating safety and tolerability from the Pivotal Phase III trial of Lupuzor™ in patients with Systemic Lupus Erythematosus (“Lupus”) Read More 12
December 17, 2019 Publication of Information Note – In advance to admission to trading on Euronext Growth Brussels Read More
June 28, 2019 Primary endpoint successfully met from the open label extension study evaluating safety and tolerability from the Pivotal Phase III trial of Lupuzor™ in patients with Systemic Lupus Erythematosus (“Lupus”) Read More
